CME in the 13F filings
Cme Group Inc · CUSIP 12572Q105
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 9 May 2024
- Managers listing it
- 30
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 28 listed it in both
- Shares listed
- 41,387,473
- combined, among listed positions
- Reported value
- $8.9bn
- combined, at the quarter end
Among the 93 comparable managers: 13 buyers (opened or added shares) and 16 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CME in Q1 2024
30 of 30 holders
Largest increases and reductions, by shares
Increases
- Invesco Ltdexisting position · 3,873,911 shares now+768,139
- Arrowstreet Capital LPexisting position · 1,806,569 shares now+586,472
- MFS Investment Managementexisting position · 2,922,515 shares now+369,810
- Renaissance Technologies LLCexisting position · 848,689 shares now+365,900
- AQR Capital Management LLCexisting position · 1,112,303 shares now+247,584
Reductions
- Capital Research Global Investorsexisting position · 3,640,266 shares now-2,951,040
- Fidelity (FMR LLC)existing position · 3,068,319 shares now-1,896,122
- Capital World Investorsexisting position · 13,184,501 shares now-1,405,366
- Neuberger Berman Group LLCexisting position · 2,427,725 shares now-1,009,633
- Janus Henderson Group Ltdexisting position · 2,167,342 shares now-800,889
New positions and exits
New (1)
Exited (1)
- Bridgewater Associates LPwas $21m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 23 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 21 | $5.0bn | n.a. | n.a. |
| Q4 2013 | 19 | $4.5bn | n.a. | n.a. |
| Q1 2014 | 18 | $4.2bn | n.a. | n.a. |
| Q2 2014 | 19 | $4.2bn | n.a. | n.a. |
| Q3 2014 | 18 | $5.1bn | n.a. | n.a. |
| Q4 2014 | 19 | $5.6bn | n.a. | n.a. |
| Q1 2015 | 22 | $5.8bn | n.a. | n.a. |
| Q2 2015 | 22 | $5.5bn | n.a. | n.a. |
| Q3 2015 | 25 | $5.2bn | n.a. | n.a. |
| Q4 2015 | 24 | $4.9bn | n.a. | n.a. |
| Q1 2016 | 26 | $5.4bn | n.a. | n.a. |
| Q2 2016 | 29 | $6.0bn | n.a. | n.a. |
| Q3 2016 | 27 | $5.8bn | n.a. | n.a. |
| Q4 2016 | 30 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 30 | $6.4bn | n.a. | n.a. |
| Q2 2017 | 35 | $7.0bn | n.a. | n.a. |
| Q3 2017 | 31 | $7.7bn | n.a. | n.a. |
| Q4 2017 | 30 | $7.8bn | n.a. | n.a. |
| Q1 2018 | 33 | $8.8bn | n.a. | n.a. |
| Q2 2018 | 32 | $9.9bn | n.a. | n.a. |
| Q3 2018 | 30 | $10.5bn | n.a. | n.a. |
| Q4 2018 | 27 | $12.4bn | n.a. | n.a. |
| Q1 2019 | 31 | $12.0bn | n.a. | n.a. |
| Q2 2019 | 28 | $14.6bn | n.a. | n.a. |
| Q3 2019 | 29 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 28 | $15.3bn | n.a. | n.a. |
| Q1 2020 | 32 | $13.4bn | n.a. | n.a. |
| Q2 2020 | 32 | $12.2bn | n.a. | n.a. |
| Q3 2020 | 32 | $11.8bn | n.a. | n.a. |
| Q4 2020 | 26 | $11.4bn | n.a. | n.a. |
| Q1 2021 | 26 | $12.3bn | n.a. | n.a. |
| Q2 2021 | 26 | $12.8bn | n.a. | n.a. |
| Q3 2021 | 30 | $11.6bn | n.a. | n.a. |
| Q4 2021 | 26 | $14.6bn | n.a. | n.a. |
| Q1 2022 | 32 | $15.8bn | n.a. | n.a. |
| Q2 2022 | 37 | $13.4bn | n.a. | n.a. |
| Q3 2022 | 38 | $10.9bn | n.a. | n.a. |
| Q4 2022 | 36 | $9.1bn | n.a. | n.a. |
| Q1 2023 | 32 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 34 | $9.5bn | n.a. | n.a. |
| Q3 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q4 2023 | 32 | $10.2bn | 18 | 14 |
| Q1 2024 | 30 | $8.9bn | 13 | 16 |
| Q2 2024 | 33 | $8.3bn | 20 | 11 |
| Q3 2024 | 35 | $10.0bn | 22 | 12 |
| Q4 2024 | 35 | $11.1bn | 16 | 15 |
| Q1 2025 | 35 | $12.1bn | 21 | 13 |
| Q2 2025 | 37 | $12.7bn | 18 | 17 |
| Q3 2025 | 33 | $11.9bn | 14 | 17 |
| Q4 2025 | 31 | $11.1bn | 20 | 26 |
| Q1 2026 | 33 | $11.4bn | 15 | 26 |
| Q2 2026 | 37 | $9.3bn | 31 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CME and V →CME and AXP →CME and BAC →Choose a stock to compare with CME →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CME, latest filings →Back to the 13F Explorer →